Cited by 794Sepsis Diagnosis and TreatmentInflammation biomarkers and pathwaysAntibiotics Pharmacokinetics and Efficacy

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Fisher, Charles J.·1994·JAMA

DOI 10.1001/jama.1994.03510470040032

Open this paper in CoChat — free account

Abstract

Objective. —To further define the safety and efficacy of recombinant human interleukin 1 receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. Study Design. —Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial. Population. —A total of 893 patients with sepsis syndrome received an intravenous loading dose of rhIL-1ra, 100 mg, or placebo followed by a continuous 72-hour intravenous infusion of rhIL-1ra (1.0 or 2.0 mg/kg per hour) or placebo. Outcome Measure. —Twenty-eight—day all-cause mortality. Results. —There was not a significant increase in survival time for rhIL-1ra treatment compared with placebo among all patients who received the study medication (n=893; generalized Wilcoxon statistic,P=.22) or among patients with shock at study entry (n=713; generalized Wilcoxon statistic,P=.23), the two primary efficacy analyses specified a priori for this trial. Results from secondary analyses suggest an increase in survival time with rhIL-1ra treatment among patients with dysfunction of one or more organs (n=563; linear dose-response,P=.009). Retrospective analysis demonstrated an increase in survival time with rhIL-1ra treatment among patients with a predicted risk of mortality of 24% or greater (n=580; linear dose-response,P=.005) as well as among patients with both dysfunction of one or more organs and a predicted risk of mortality of 24% or greater (n=411; linear dose-response,P=.002). Conclusions. —There was not a statistically significant increase in survivial time for rhIL-1ra treatment compared with placebo among all patients who received the study medication or among patients with shock at study entry. Secondary and retrospective analyses of efficacy suggest that treatment with rhIL-1ra results in a dose-related increase in survival time among patients with sepsis who have organ dysfunction and/or a predicted risk of mortality of 24% or greater. (JAMA. 1994;271:1836-1843)

Integrity signals

Registry

Crossref · 10.1001/jama.1994.03510470040032

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The publisher hasn’t deposited this paper’s reference list.

Sorted by citations

Items 301–400 of 794

Galantamine protects against lipopolysaccharide-induced acute lung injury in rats
Li, G., Zhou, C., Zhou, Q., & Zou, H. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20155008 · Cited by 46
An improved clinically relevant sepsis model in the conscious rat
Mathiak, G., Szewczyk, D., Abdullah, F., Ovadia, P., Feuerstein, G., & Rabinovici, R. (2000) · Critical Care Medicine · doi:10.1097/00003246-200006000-00043 · Cited by 46
Inclusion Criteria for Clinical Trials in Sepsis
Trzeciak, S. W., Zanotti-Cavazzoni, S. L., Parrillo, J. E., & Dellinger, R. P. (2005) · CHEST Journal · doi:10.1378/chest.127.1.242 · Cited by 46
The Systemic Inflammatory Response Syndrome
Toliver-Kinsky, T. E., Kobayashi, M., Suzuki, F., et al. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-47661-4.00019-8 · Cited by 46
Release of anti-inflammatory mediators after major torso trauma correlates with the development of postinjury multiple organ failure
Partrick, D. A., Moore, E. E., Moore, F. A., Biffl, W. L., & Barnett, C. C. (1999) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)00240-8 · Cited by 47
Polymorphisms in the IL‐1 gene cluster influence systemic inflammation in patients at risk for acute‐on‐chronic liver failure
Alcaraz‐Quiles, J., Titos, E., Casulleras, M., Pavesi, M., López‐Vicario, C., Rius, B., Lopategi, A., Gottardi, A. D., Graziadei, I. W., Grønbæk, H., et al. (2016) · Hepatology · doi:10.1002/hep.28896 · Cited by 45
“Notably, recombinant human IL-1ra treatment has been shown to be effective in critically ill pediatric patients (34) and in patients with sepsis and organ dysfunction and/or a predicted risk of mortality of 24% or greater (35).”
Background
Adults with septic shock and extreme hyperferritinemia exhibit pathogenic immune variation
Kernan, K. F., Ghaloul‐Gonzalez, L., Shakoory, B., Kellum, J. A., Angus, D. C., & Carcillo, J. A. (2018) · Genes and Immunity · doi:10.1038/s41435-018-0030-3 · Cited by 45
Anti-cytokine and anti-inflammatory therapies for the treatment of severe sepsis: progress and pitfalls
Minnich, D. J., & Moldawer, L. L. (2004) · Proceedings of The Nutrition Society · doi:10.1079/pns2004378 · Cited by 44
“These therapies have included monoclonal antibodies against TNF-a (Fisher et al. 1993; Cohen & Carlet, 1996; Abraham et al. 1995, 1998), soluble TNF receptors (Fisher et al. 1996; Abraham et al. 1997), IL-1 receptor antagonists and soluble IL-1 receptors (Fisher et al. 1994a,b,c; Opal et al. 1997).”
Background
Protective Effect of Ginsenosides Rg1 and Re on Lipopolysaccharide-Induced Sepsis by Competitive Binding to Toll-Like Receptor 4
Su, F., Xue, Y., Wang, Y., Zhang, L., Chen, W., & Hu, S. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01381-15 · Cited by 45
“In fact, agents targeting a single mediator such as anti-TNF- monoclonal antibody and IL-1 receptor antagonist are usually ineffective in the treatment of sepsis, since other inflammatory signaling pathways are not controlled (31, 32).”
Background
Transient Receptor Potential Melastatin 2 Protects Mice against Polymicrobial Sepsis by Enhancing Bacterial Clearance
Qian, X., Numata, T., Zhang, K., Li, C., Hou, J., Mori, Y., & Fang, X. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000275 · Cited by 44
The Natural History of the Systemic Inflammatory Response Syndrome and the Evaluation of SIRS Criteria as a Predictor of Severity in Patients Hospitalized through Emergency Services.
Sun, D., & Aikawa, N. (1999) · The Keio Journal of Medicine · doi:10.2302/kjm.48.28 · Cited by 44
Multivariable predictive models for adverse outcome of invasive meningococcal disease in children
Malley, R., Huskins, W. C., & Kuppermann, N. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)70153-1 · Cited by 44
Cytokine-Related Genotypic Differences in Peak Interleukin-6 Blood Levels of Patients with SIRS and Septic Complications
Watanabe, E., Hirasawa, H., Oda, S., Shiga, H., Matsuda, K., Nakamura, M., Abe, R., & Nakada, T. (2005) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-200511000-00025 · Cited by 42
The role of extracellular vesicle fusion with target cells in triggering systemic inflammation
Papareddy, P., Tapken, I., Kroh, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45125-1 · Cited by 42
Targeting cytokines as a treatment for patients with sepsis: A lost cause or a strategy still worthy of pursuit?
Brown, K. A., Brown, G., Lewis, S. M., Beale, R. J., & Treacher, D. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.04.041 · Cited by 41
The Cost-Benefit of a Randomized Trial to a Health Care Organization
Hornberger, J. C., & Eghtesady, P. (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00098-6 · Cited by 42
“Several recently conducted large trials have revealed variable effects of agents on survival in patients with established septic shock [31–38].”
Background
Plasma concentrations and anti-L-cytokine effects of α-melanocyte stimulating hormone in septic patients
Catania, A., Cutuli, M., Garofalo, L., et al. (2000) · Critical Care Medicine · doi:10.1097/00003246-200005000-00024 · Cited by 42
“Therefore, therapeutic strategies have included the same anti-L-cytokine and anti-inflammatory molecules used to treat other forms of inflammation (3-5).”
Background
Bride and groom in systemic inflammation – The bells ring for complement and Toll in cooperation
Barratt‐Due, A., Pischke, S. E., Brekke, O., Thorgersen, E. B., Nielsen, E. W., Espevik, T., Huber-Lang, M. S., & Mollnes, T. E. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.07.019 · Cited by 40
Efficacy Versus Safety Concerns for Aerosol Chemotherapy in Non-Small-Cell Lung Cancer: A Future Dilemma for Micro-Oncology
Darwiche, K., Zarogoulidis, P., Karamanos, N. K., et al. (2013) · Future Oncology · doi:10.2217/fon.12.205 · Cited by 41
Economic evaluation of new therapies in critical illness
Coughlin, M. T., & Angus, D. C. (2003) · Critical Care Medicine · doi:10.1097/00003246-200301001-00002 · Cited by 41
Perifollicular Transgenic Expression of Human Interleukin-1 Receptor Antagonist Protein following Topical Application of Novel Liposome-Plasmid DNA Formulations In Vivo
Niemiec, S. M., Latta, J. M., Ramachandran, C., et al. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js9604873 · Cited by 41
Supplemental immune globulins in sepsis: a critical appraisal
Werdan, K., & Pilz, G. (1996) · Clinical & Experimental Immunology · doi:10.1111/cei.1996.104.s1.83 · Cited by 41
Innate Immunity: A Cutaneous Perspective
Goodarzi, H., Trowbridge, J. M., & Gallo, R. L. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-0037-4 · Cited by 42
Stem Cells in Sepsis
Weil, B. R., Markel, T. A., Herrmann, J. L., Abarbanell, A. M., Kelly, M. L., & Meldrum, D. R. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181a77b9c · Cited by 39
Operative and nonoperative therapy of intraabdominal infections
Wittmann, D. H. (1998) · Infection · doi:10.1007/bf02962267 · Cited by 40
State-of-the-art therapy for severe sepsis and multisystem organ dysfunction
Awad, S. S. (2003) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2003.10.004 · Cited by 39
The Phosphoinositide-3 Kinase Survival Signaling Mechanism in Sepsis
Manukyan, M. C., Weil, B. R., Wang, Y., Abarbanell, A. M., Herrmann, J. L., Poynter, J. A., & Meldrum, D. R. (2010) · Shock · doi:10.1097/shk.0b013e3181e14ea9 · Cited by 38
THE INNATE IMMUNE RESPONSE TO SECONDARY PERITONITIS
van Till, J. W. O., van Veen, S. Q., van Ruler, O., et al. (2007) · Shock · doi:10.1097/shk.0b013e318063e6ca · Cited by 39
“However, therapeutic inhibition of IL-1" and TNF-! has not shown a significant impact on survival in human sepsis (106, 107).”
Background
Anticancer Agent 2-Methoxyestradiol Improves Survival in Septic Mice by Reducing the Production of Cytokines and Nitric Oxide
Yeh, C., Chou, W., Chu, C., So, E. C., Chang, H.-C., Wang, J.-J., & Hsing, C. (2011) · Shock · doi:10.1097/shk.0b013e318231866f · Cited by 39
“Recent clinical trials of agents directed against cytokines such as TNF-! or IL1" have failed to improve the survival of patients with sepsis (3, 4, 29, 30).”
Background
Clinical trials in spontaneous disease in dogs: a new paradigm for investigations of sepsis
Otto, C. M. (2007) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/j.1476-4431.2007.00249.x · Cited by 39
Evolution of the Concept of Sepsis
Vincent, J. (2022) · Antibiotics · doi:10.3390/antibiotics11111581 · Cited by 38
Multidrug resistant (or antimicrobial-resistant) pathogens - alternatives to new antibiotics?
Brunel, A.-S., & Guery, B. P. (2017) · Swiss Medical Weekly · doi:10.4414/smw.2017.14553 · Cited by 40
Biomaterial-Driven Immunomodulation: Cell Biology-Based Strategies to Mitigate Severe Inflammation and Sepsis
Lasola, J. J., Kamdem, H., McDaniel, M. W., & Pearson, R. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01726 · Cited by 38
Severe sepsis and Toll-like receptors
Gao, H., Leaver, S. K., Burke-Gaffney, A. C., & Finney, S. J. (2007) · Seminars in Immunopathology · doi:10.1007/s00281-007-0101-4 · Cited by 38
“Targeting single cytokines such as TNF-α or IL-1 has not been effective [89, 90].”
Background
Definition of sepsis: Not quite time to dump SIRS?*
Marik, P. E. (2002) · Critical Care Medicine · doi:10.1097/00003246-200203000-00039 · Cited by 38
Techniques of extracorporeal cytokine removal: a systematic review of human studies
Atan, R., Crosbie, D., & Bellomo, R. (2013) · Renal Failure · doi:10.3109/0886022x.2013.815089 · Cited by 37
Mediator modulation therapy of severe sepsis and septic shock: Does it work? *
Dellinger, R. P., & Parrillo, J. E. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000105423.06091.8e · Cited by 37
Manipulation of local and systemic host defence in the prevention of perioperative sepsis
Windsor, A. C. J., Klava, A., Somers, S. S., et al. (1995) · British journal of surgery · doi:10.1002/bjs.1800821106 · Cited by 37
Cytokine - Processing Enzymes: Stopping the cuts
Dinarello, C. A., & Margolis, N. (1995) · Current Biology · doi:10.1016/s0960-9822(95)00116-3 · Cited by 37
Novel Approaches to the Prevention and Therapy of Neonatal Bacterial Sepsis
Pérez, E. M. R., & Weisman, L. E. (1997) · Clinics in Perinatology · doi:10.1016/s0095-5108(18)30193-3 · Cited by 37
Lexipafant and Acute Pancreatitis: A Critical Appraisal of the Clinical Trials
Abu‐Zidan, F. M., & Windsor, J. A. (2002) · The European Journal of Surgery · doi:10.1080/11024150260102816 · Cited by 37
Clinical trials for the treatment of sepsis
THUS, L. G. (1995) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.1995.tb04266.x · Cited by 37
Distinct immunologic endotypes are associated with clinical trajectory after severe blunt trauma and hemorrhagic shock
Brakenridge, S. C., Wang, Z., Cox, M. C., Raymond, S. L., Hawkins, R. B., Darden, D. B., Ghita, G. L., Brumback, B., Cuschieri, J., Maier, R. V., et al. (2020) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000003029 · Cited by 37
T-5224, a selective inhibitor of c-Fos/activator protein-1, improves survival by inhibiting serum high mobility group box-1 in lethal lipopolysaccharide-induced acute kidney injury model
Ishida, M., Ueki, M., Morishita, J., Ueno, M., Shiozawa, S., & Nobuhiro Maekawa, A. (2015) · Journal of Intensive Care · doi:10.1186/s40560-015-0115-2 · Cited by 37
“However, clinical trials with anticytokine agents, such as anti-TNF-α antibodies and soluble IL-1 receptor antagonists, have proven ineffective in the treatment of sepsis [14, 15].”
Background
Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 Pandemic
Paolera, S. D., Valencic, E., Piscianz, E., Moressa, V., Tommasini, A., Sagredini, R., Kiren, V., Comar, M., & Taddio, A. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2020.624248 · Cited by 36
“Its use showed beneficial effects even in other inflammatory conditions such as severe sepsis in adults (20) or secondary hemophagocytic lymphohistiocytosis (sHLH) in pediatric patients (21).”
Background
The Multifaceted Effects of Polysaccharides Isolated from Dendrobium huoshanense on Immune Functions with the Induction of Interleukin-1 Receptor Antagonist (IL-1ra) in Monocytes
Lin, J., Chang, Y., Yang, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094040 · Cited by 36
Transcription Factor NFκB Expression and Postsurgical Organ Dysfunction
Foulds, S., Galustian, C., Mansfield, A. O., & Schächter, M. (2001) · Annals of Surgery · doi:10.1097/00000658-200101000-00012 · Cited by 35
Constitutive expression of interleukin-1α precursor promotes human vascular smooth muscle cell proliferation
Beasley, D., & Cooper, A. L. (1999) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1999.276.3.h901 · Cited by 36
Tumor Necrosis Factor (TNF)–α–Induced Interleukin‐8 in Human Blood Cultures Discriminates Neutralization by the p55 and p75 TNF Soluble Receptors
Frishman, J. I., Edwards, C. K., Sonnenberg, M. G., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/317605 · Cited by 36
A NOVEL INHIBITORY PEPTIDE OF TOLL-LIKE RECEPTOR SIGNALING LIMITS LIPOPOLYSACCHARIDE-INDUCED PRODUCTION OF INFLAMMATORY MEDIATORS AND ENHANCES SURVIVAL IN MICE
Tsung, A., McCoy, S. L., Klune, J. R., et al. (2007) · Shock · doi:10.1097/01.shk.0000239773.95280.2c · Cited by 36
Influence of Severity of Illness on the Effects of Eritoran Tetrasodium (E5564) and on Other Therapies for Severe Sepsis
Kalil, A. C., LaRosa, S. P., Gogate, J. P., Lynn, M., & Opal, S. M. (2011) · Shock · doi:10.1097/shk.0b013e318227980e · Cited by 35
“Eight studies evaluating six different therapies were included IL-1 receptor antagonist (IL-1ra) (5), antithrombin (6), DAA (7, 8), unfractionated heparin (9), p55 tumor necrosis factor receptor fusion protein (p55 TNFr) (10), and tissue factor pathway inhibitor (TFPI) (11, 12).”
BackgroundMethodInfluential
Statins role in the prevention and treatment of sepsis
Dobesh, P. P., & Olsen, K. M. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.04.010 · Cited by 35
Combination Therapy of 15-Epi-Lipoxin A4 With Antibiotics Protects Mice From Escherichia coli–Induced Sepsis*
Ueda, T., Fukunaga, K., Seki, H., Miyata, J., Arita, M., Miyasho, T., Obata, T., Asano, K., Betsuyaku, T., & Takeda, J. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000162 · Cited by 35
Ethyl pyruvate reduces mortality in an endotoxin-induced severe acute lung injury mouse model
Shang, G.-H., Lin, D., Xiao, W. L., Jia, C.-Q., Li, Y., Wang, A., & Dong, L. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-91 · Cited by 36
“However, in two large clinical trails, administration of a monoclonal antibody against human TNF- (TNF- MAb) and a recombinant human IL-1 (rhIL-1ra) receptor antagonist failed to prolong survival in patients with sepsis syndrome [5,6].”
Background
HELP Apheresis in the Treatment of Sepsis
Samtleben, Samtleben, Bengsch, et al. (1998) · Artificial Organs · doi:10.1046/j.1525-1594.1998.06011.x · Cited by 35
Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon
Solórzano, C. C., Kaibara, A., Hess, P. J., Edwards, P. D., Ksontini, R., Abouhamze, A. S., McDaniel, S., Frazier, J., Trujillo, D., Kieft, G. L., et al. (1998) · Journal of Applied Physiology · doi:10.1152/jappl.1998.84.4.1119 · Cited by 34
Multiple Organ Failure in Septic Shock
THUS, L. G., Groeneveld, A. B. J., & Hack, C. E. (1996) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-80186-0_10 · Cited by 34
Clinical trial design for unmet clinical needs: a spotlight on sepsis
Vincent, J., & Sakr, Y. L. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1643235 · Cited by 34
Sepsis Induced by Cecal Ligation and Puncture
Gong, W., & Wen, H. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9167-9_22 · Cited by 34
Interleukin-1 receptor type I gene-deficient bile duct-ligated mice are partially protected against endotoxin
Sewnath, M. E., van der Poll, T., ten Kate, F. J. W., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.30272 · Cited by 34
Downregulation of the Proinflammatory Cytokine Response to Endotoxin by Pretreatment With the Nontoxic Lipid A Analog SDZ MRL 953 in Cancer Patients
Kiani, A., Tschiersch, A., Gaboriau, E., Otto, F., Seiz, A., Knopf, H. P., Stütz, P., Färber, L., Haus, U., Galanos, C., et al. (1997) · Blood · doi:10.1182/blood.v90.4.1673.1673_1673_1683 · Cited by 37
In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii
Ricci, S., Macchia, G., Ruggiero, P., Maggi, T., Bossù, P., Xu, L., Medaglini, D., Tagliabue, A., Hammarström, L. L. G., Pozzi, G., et al. (2003) · BMC Biotechnology · doi:10.1186/1472-6750-3-15 · Cited by 33
Epithelial transport during septic acute kidney injury
Morrell, E. D., Kellum, J. A., Hallows, K. R., & Pastor‐Soler, N. M. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft503 · Cited by 33
PC-SPES: A Potent Inhibitor of Nuclear Factor-κB Rescues Mice from Lipopolysaccharide-Induced Septic Shock
Ikezoe, T., Yang, Y., Heber, D., et al. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.6.1521 · Cited by 33
The Prospect of Treating Rheumatoid Arthritis with Recombinant Human Interleukin-1 Receptor Antagonist
Bresnihan, B. (2001) · BioDrugs · doi:10.2165/00063030-200115020-00003 · Cited by 33
How to use an article on therapy or prevention
Cook, D. J., Hébert, P. C., Heyland, D. K., Guyatt, G. H., Brun‐Buisson, C., Marshall, J. C., Russell, J. E., Vincent, J., Sprung, C. L., & Rutledge, F. S. (1997) · Critical Care Medicine · doi:10.1097/00003246-199709000-00017 · Cited by 33
Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis
Tsirigotis, P. D., Chondropoulos, S. D., Gkirkas, K., Meletiadis, J., & Dimopoulou, I. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.03.47 · Cited by 33
Innate immune recognition and inflammation in Neisseria meningitidis infection
Johswich, K. O. (2017) · Pathogens and Disease · doi:10.1093/femspd/ftx022 · Cited by 31
“Also, administration of IL-1ra to sepsis patients did not enhance survival rates (Fisher et al. 1994; Opal et al. 1997).”
Background
Management and Cure of Gouty Arthritis
Keller, S. F., & Mandell, B. F. (2022) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2022.03.001 · Cited by 37
Immune-modulating therapy in acute pancreatitis: Fact or fiction
Akinosoglou, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15200 · Cited by 34
SEPTIC STOCK
Butt, W. W. (2001) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70330-8 · Cited by 32
Intrahepatic nuclear factor-κ B activity and α 1-acid glycoprotein transcription do not predict outcome after cecal ligation and puncture in the rat
Chen, J., Raj, N. R., Kim, P., Andrejko, K. M., & Deutschman, C. S. (2001) · Critical Care Medicine · doi:10.1097/00003246-200103000-00021 · Cited by 31
Non-cardiogenic Pulmonary Oedema in Vascular Surgery
Pararajasingam, R., Nicholson, M. L., Bell, P. R. F., & Sayers, R. D. (1999) · European Journal of Vascular and Endovascular Surgery · doi:10.1053/ejvs.1998.0750 · Cited by 31
Changes in cardiac lipid metabolism during sepsis: The essential role of very low-density lipoprotein receptors
Jia, L., Takahashi, M., MORIMOTO, H., et al. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.11.014 · Cited by 30
Surgical sepsis: dysregulation of immune function and therapeutic implications
Boontham, P., Chandran, P., Rowlands, B. J., & Eremin, O. (2003) · The Surgeon · doi:10.1016/s1479-666x(03)80018-5 · Cited by 30
The cytokine response to critical illness.
Foex, B. A., & Shelly, M. P. (1996) · Emergency Medicine Journal · doi:10.1136/emj.13.3.154 · Cited by 30
Sepsis in the critically ill patient: current and emerging management strategies
Heming, N., Azabou, É., Cazaumayou, X., Moine, P., & Annane, D. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1846522 · Cited by 32
The Tyrosine Kinase Inhibitor Tyrphostin AG126 Reduces the Development of Acute and Chronic Inflammation
Cuzzocrea, S., McDonald, M. C., Mazzon, E., et al. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64526-9 · Cited by 29
Influence of alterations in forgoing life-sustaining treatment practices on a clinical sepsis trial
Sprung, C. L., Eidelman, L. A., Pizov, R., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199703000-00002 · Cited by 29
Self-citation
A two-decade journey in identifying high mobility group box 1 (HMGB1) and procathepsin L (pCTS-L) as potential therapeutic targets for sepsis
Li, J., Zhu, S., He, L., et al. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2239495 · Cited by 28
Immunomodulatory drugs in sepsis: a systematic review and meta‐analysis
Robey, R. C., Logue, C., Caird, C. A., Hansel, J., Hellyer, T. P., Simpson, J. A., Dark, P. M., Mathioudakis, A. G., & Felton, T. (2024) · Anaesthesia · doi:10.1111/anae.16263 · Cited by 35
“Consequently, early trials focused on drugs that blocked components of the in ﬂ ammatory cascade such as tumour necrosis factor a (TNF a ) antagonists [5] and interleukin (IL)-1 receptor antagonists [6].”
New Decade, Old Debate: Blocking the Cytokine Pathways in Infection-Induced Cytokine Cascade
Rizvi, M. S., & de Moraes, A. G. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000364 · Cited by 27
The double sides of NLRP3 inflammasome activation in sepsis
Vigneron, C., Py, B. F., Monneret, G., & Venet, F. (2023) · Clinical Science · doi:10.1042/cs20220556 · Cited by 34
α‐Haemolysin production, as a single factor, causes fulminant sepsis in a model of Escherichia coli ‐induced bacteraemia
Johnsen, N., Hamilton, A., Greve, A., Christensen, M. G., Therkildsen, J. R., Wehmöller, J., Skals, M., & Prætorius, H. A. (2019) · Cellular Microbiology · doi:10.1111/cmi.13017 · Cited by 27
Trauma is danger
Hwang, P. F., Porterfield, N., Pannell, D., Davis, T. A., & Elster, E. A. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-92 · Cited by 27
Intermedin1–53 Protects Cardiac Fibroblasts by Inhibiting NLRP3 Inflammasome Activation During Sepsis
Wu, D., Shi, L., Li, P., et al. (2017) · Inflammation · doi:10.1007/s10753-017-0706-2 · Cited by 27
Increasing the Efficacy of Anti-Inflammatory Agents Used in the Treatment of Sepsis
Minneci, P. C., Deans, K. J., Natanson, C., & Eichacker, P. Q. (2003) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-002-0857-3 · Cited by 25
Acute lung injury and the acute respiratory distress syndrome
Cheng, I. W., & Matthay, M. A. (2003) · Critical Care Clinics · doi:10.1016/s0749-0704(03)00050-2 · Cited by 26
Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation
Cremer, P. C., Sheng, C. C., Sahoo, D. H., Dugar, S. P., Prada, R. A., Wang, T. K. M., Hassan, O. K. A., Hernandez-Montfort, J., Wolinsky, D. A., Culver, D. A., et al. (2021) · European Heart Journal Open · doi:10.1093/ehjopen/oeab002 · Cited by 27
Distinctive Cytokines as Biomarkers Predicting Fatal Outcome of Severe Staphylococcus aureus Bacteremia in Mice
van den Berg, S., Laman, J. D., Boon, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059107 · Cited by 26
Endogenous interleukin-4 and interleukin-10 regulate experimental lung ischemia reperfusion injury
Farivar, A. S., Krishnadasan, B., Naidu, B. V., et al. (2003) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(03)00335-7 · Cited by 26
Septic Shock
Klosterhalfen, B., & Bhardwaj, R. S. (1998) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(97)00424-2 · Cited by 26
Role of moesin in HMGB1-stimulated severe inflammatory responses
Han, M.-S., Lee, Y.-M., Kim, S.-W., Kim, K.-M., Lee, T., Lee, W., Kwon, O. K., Lee, S., & Bae, J.-E. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0969 · Cited by 27
Short-Term Organ Dysfunction Is Associated With Long-Term (10-Yr) Mortality of Septic Shock
Linder, A., Lee, T., Fisher, J., et al. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001843 · Cited by 25
Meta-analysis of Clinical Trials
Sun, J., Freeman, B. D., & Natanson, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-849905-4.00022-8 · Cited by 26
Interleukin-1 receptor antagonist restores homeostatic function and limits multiorgan damage in heatstroke
Shen, K. H., Chang, C. K., Lin, M.-T., & Chang, C. (2008) · European Journal of Applied Physiology · doi:10.1007/s00421-008-0755-1 · Cited by 26
Elevated interleukin-1 receptor antagonist levels in pediatric sepsis syndrome
Samson, L. M., Allen, U., Creery, W. D., et al. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70067-2 · Cited by 25
Perspektiven in der Schockforschung
Menger, M. D., & Vollmar, B. (2006) · Notfall + Rettungsmedizin · doi:10.1007/s10049-006-0855-6 · Cited by 25
Biologics and JAK inhibitors for the treatment of monogenic systemic autoinflammatory diseases in children
Du, Y., Liu, M., Nigrovic, P. A., Dedeoğlu, F., & Lee, P. Y. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.12.816 · Cited by 24
Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review
Charlesworth, J. E. G., & Kavirayani, A. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14029 · Cited by 25

Authors: Fisher, C. J.
Corresponding author: Fisher, Charles J.
ORCID: Fisher, Charles J.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 1994-06-15
Volume: 271
Issue: 23
Pages: 1836
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.1994.03510470040032
OpenAlex: W4322697531
Cited by: 790
References: 0
Citations by year: 2026: 11 · 2025: 23 · 2024: 18 · 2023: 28 · 2022: 15 · 2021: 18 · 2020: 32 · 2019: 23 · 2018: 24 · 2017: 22 · 2016: 19 · 2015: 18 · 2014: 30 · 2013: 20 · 2012: 22
FWCI: 37.99
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
Topics: Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Keywords: sepsis, septic shock, survival, organ dysfunction, mortality risk, dose-response relationship, drug safety, cytokine inhibition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks